Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18237492 | 0.95 | L3MBTL1 (0.40) | L3MBTL1MTNR1AMTNR1BSMN1; SMN2NPC1 | |
| SCHEMBL21097761 | 0.81 | KDM4E (0.37) | L3MBTL1MTNR1AMTNR1BSMN1; SMN2NPC1 | |
| SCHEMBL18227294 | 0.78 | NPC1 (0.50) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A | |
| SCHEMBL18227261 | 0.78 | KDM4E (0.56) | L3MBTL1MTNR1AMTNR1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL18237352 | 0.76 | KMT2A (0.40) | L3MBTL1MTNR1AMTNR1BSMN1; SMN2NPC1 | |
| SCHEMBL18237430 | 0.73 | HTR7 (0.37) | L3MBTL1MTNR1AMTNR1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL19152744 | 0.72 | KDM4E (0.48) | L3MBTL1MTNR1AMTNR1BALDH1A1KDM4E | |
| SCHEMBL14125305 | 0.72 | KDM4E (0.48) | L3MBTL1MTNR1AMTNR1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL18237454 | 0.70 | SMN1; SMN2 (0.37) | L3MBTL1SMN1; SMN2NPC1RAB9AHPGD | |
| SCHEMBL21388581 | 0.70 | NPC1 (0.42) | L3MBTL1SMN1; SMN2NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11497757-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO INC (US) | 2022-06-16 | — | — | US | disclosed |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. | 2021-06-03 | — | — | US | disclosed |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | BLINKBIO, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10716801-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10716801-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10064880-B2 | Silanol based therapeutic payloads | BLINKBIO, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | BLINKBIO INC (US) | 2018-07-19 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| WO-2017214491-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214491-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | L3MBTL1 669/4885MTNR1A 3961/4885MTNR1B 4306/4885 |
| US-11497757-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | L3MBTL1 479/4885MTNR1A 3713/4885MTNR1B 4674/4885 |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | CD44, MSN, AS3MT | L3MBTL1 669/4885MTNR1A 3961/4885MTNR1B 4306/4885 |
| US-20210161921-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | L3MBTL1 479/4885MTNR1A 3713/4885MTNR1B 4674/4885 |
| US-10716801-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | L3MBTL1 479/4885MTNR1A 3713/4885MTNR1B 4674/4885 |
| US-20180200273-A1 | Silanol Based Therapeutic Payloads | CD47, CD4, BST2 | L3MBTL1 479/4885MTNR1A 3713/4885MTNR1B 4674/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | L3MBTL1 669/4885MTNR1A 3961/4885MTNR1B 4306/4885 |
| US-20220184104-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | CD47, CD4, BST2 | L3MBTL1 479/4885MTNR1A 3713/4885MTNR1B 4674/4885 |
| US-10064880-B2 | Silanol based therapeutic payloads | CD47, CD4, BST2 | L3MBTL1 479/4885MTNR1A 3713/4885MTNR1B 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.